Mercury Laboratories schedules board meeting to approve Q2 2026 unaudited results

What Mercury Laboratories announced

Mercury Laboratories Ltd filed a notice with BSE on 16 July 2026 stating that the Board of Directors will convene on 25 July 2026. The primary agenda is to consider and approve the unaudited financial results for the quarter ended 30 June 2026. The notice also references “other agenda items” but does not elaborate on their nature.

Board meeting details

• Date of meeting: 25 July 2026
• Venue: Not specified in the filing
• Purpose: Approval of unaudited financial results for Q2 FY2026 (quarter ended 30 June 2026)
• Filing date: 16 July 2026, 12:08:20 UTC
• Security code: BSE 538964 (no NSE code disclosed)

The filing is a standard statutory intimation required under the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations. It does not contain any quantitative financial data, management commentary, or forward‑looking statements.

Agenda of the meeting

While the notice highlights the approval of unaudited results, it also mentions “other agenda items”. The filing does not provide a breakdown of these items, and therefore no further detail can be extracted.

Key facts at a glance

Why this matters for investors

The filing confirms that Mercury Laboratories will formally review its Q2 FY2026 performance on 25 July 2026. Approval of unaudited results is a routine step before audited figures are released, and it signals that the company is on schedule with its statutory reporting obligations. Because no financial numbers are disclosed, investors cannot assess performance from this notice alone. However, the timing of the board meeting may give an indication of when the audited results could be expected, subject to the usual audit completion timeline.

Conclusion

Mercury Laboratories has announced a board meeting on 25 July 2026 to approve its unaudited financial results for the quarter ended 30 June 2026. The filing does not provide any quantitative results or details of other agenda items. Shareholders will need to await the subsequent release of the audited financial statements for a complete view of the company's performance.